焦臣宇

MSTO1 promotes hepatocellular carcinoma progression and represents a potential target for immunotherapy

The incidence of hepatocellular carcinoma (HCC) has increased over recent decades. While significant progress has been achieved in immunotherapy, the five-year survival rate is still unsatisfactory because of the low response rate and acquired resistance in a few patients, which...